CRL — Charles River Laboratories International Balance Sheet
0.000.00%
Last trade - 00:00
- $11.68bn
- $14.12bn
- $4.13bn
- 94
- 36
- 90
- 86
2019 December 28th | 2020 December 26th | 2021 December 25th | 2022 December 31st | 2023 December 30th | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 239 | 229 | 242 | 235 | 277 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 514 | 618 | 650 | 752 | 780 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,021 | 1,201 | 1,274 | 1,439 | 1,609 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,184 | 1,303 | 1,584 | 1,857 | 2,034 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 4,693 | 5,491 | 7,024 | 7,603 | 8,195 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 710 | 840 | 1,033 | 1,092 | 1,055 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,058 | 3,376 | 4,489 | 4,626 | 4,598 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 1,635 | 2,115 | 2,535 | 2,976 | 3,597 |
Total Liabilities & Shareholders' Equity | 4,693 | 5,491 | 7,024 | 7,603 | 8,195 |
Total Common Shares Outstanding |